Sab Biotherapeutics, Inc. (SABSW) Stock Price & Analysis
Sab Biotherapeutics, Inc. (SABSW) rose 34.23% to USD 0.01 as of July 26, 2026 at 09:24 UTC, according to Nexqual real-time market data.
SABSW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 9,797 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, July 26, 2026 at 09:24 UTC.
Key Statistics (as of July 26, 2026 at 09:24 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 34.23% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.05 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 9,797 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (SABSW)
Wall Street analysts rate SABSW "None", per Nexqual as of July 26, 2026 at 09:24 UTC.
| Consensus Rating | None |
|---|
Earnings (SABSW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, July 26, 2026 at 09:24 UTC.
Financials & Fundamentals (SABSW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -0.32% |
| Debt / Equity | 2.72 |
| Current Ratio | 11.45 |
| Total Cash | $107.39M |
| Total Debt | $6.17M |
| Free Cash Flow | $-26.64M |
Source: Nexqual, July 26, 2026 at 09:24 UTC.
Financial Health Score (SABSW)
Nexqual rates Sab Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 09:24 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $107M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$51M |
| Efficiency | Critical — ROE -0%, ROA -25.4% |
Ownership (SABSW)
| Float | 41.20M |
|---|
Source: Nexqual, July 26, 2026 at 09:24 UTC.
Leadership (SABSW)
Sab Biotherapeutics, Inc. is led by Samuel J. Reich (age 50), CEO & Director, per Nexqual as of July 26, 2026 at 09:24 UTC.
| CEO & Director | Samuel J. Reich (age 50) |
|---|---|
| Co-Founder, President & Director | Eddie Joe Sullivan (age 58) |
| Executive VP & CFO | Lucy To (age 39) |
| Executive VP & COO | Christoph Bausch (age 54) |
| Vice President of Investor Relations & Corporate Communications | Cristi Barnett |
Major Backers & Investors (SABSW)
Notable institutional backers of Sab Biotherapeutics, Inc. include LMR Partners LLP, Morgan Stanley, Clear Street Group Inc., according to Nexqual as of July 26, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| LMR Partners LLP | 9.38% |
| Morgan Stanley | 2.55% |
| Clear Street Group Inc. | 1.37% |
| Gts Securities LLC | 0.71% |
Source: Nexqual, July 26, 2026 at 09:24 UTC.
From Sab Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Proprietary Production Platform Overview Our proprietary production platform gives us the unique ability to generate targeted, hIgG without the need for human donors or plasma.
- Using advanced genetic engineering and antibody science, we developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
- Our proprietary platform holds the potential to generate additional novel therapeutic candidates to expand our pipeline, utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets of interest.
- SAFEGUARD, the Company's multicenter, global, randomized, double-blind, placebo-controlled Phase 2b clinical trial, is designed and powered as a registrational program across multiple regions, including the United States, EMA-member states, the United Kingdom, Australia, and New Zealand.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | USD 3.51 | ▼ 1.96% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0.01 | ▼ 7.69% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 1.01% |
| SRZNW | Surrozen, Inc. Warrant | USD 0.02 | ▼ 1.28% |
| HUMAW | Humacyte, Inc. | USD 0.01 | ▲ 1.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:24 UTC. This page is informational and not investment advice.